AbbVie agreed to buy Apogee Therapeutics for $135.11 a share in cash, valuing the clinical-stage biotech at about $10.9 billion. That is a premium of roughly 50% over where Apogee closed Friday. The stock is trading near $133, up about 47%, just under the offer price. The gap between the two reflects the usual deal risk, since the agreement still needs shareholder and regulatory approval and is expected to close in the third quarter.
Both boards approved the deal unanimously. What stands out is the price tag for a company with no approved product and no revenue from sales.
The whole bet is one drug
Apogee's lead asset is APG777, also called zumilokibart. It is an antibody that targets a protein called IL-13, the same pathway behind atopic dermatitis, the chronic skin condition better known as severe eczema. The drug is engineered with a long half-life, which means patients could need far fewer injections than current options. In a mid-stage trial, about two-thirds of patients saw their skin clear at 16 weeks. The drug is set to enter Phase 3, the final testing stage, in the second half of this year.
AbbVie is positioning APG777 as a challenger to Dupixent, the Regeneron and Sanofi blockbuster that generates more than $14 billion a year treating the same condition. Less frequent dosing is the wedge. If APG777 works in late-stage trials and reaches the market with a longer gap between shots, it could take share in a category where convenience drives prescriptions.
Why AbbVie is reaching for pipeline
AbbVie spent years living off Humira, its immunology giant that lost patent protection and now faces cheap copies. The company replaced that revenue with two newer immunology drugs, Skyrizi and Rinvoq, which are carrying growth today. Buying Apogee deepens the same playbook: own the next wave of immune-system and skin-disease treatments before rivals do.
The market liked the logic. AbbVie shares are up about 6.9%, unusual for a company spending $10.9 billion, since acquirers often fall on deal news. AbbVie carries a market cap near $409 billion and a dividend yield around 2.8%. The catch is timing. AbbVie said the deal only adds to adjusted earnings starting in 2032, so this is a long-dated pipeline bet, not a near-term profit boost.
What to Watch From Here
The real catalyst is data. APG777 still has to clear Phase 3, and atopic dermatitis trials have humbled drugmakers before. Apogee holders should note the stock trades below the cash offer, which prices in the chance the deal slips or draws regulatory questions. The wider signal is a pharma dealmaking wave: large drugmakers staring at patent cliffs are paying up for clinical-stage biotech, and a $10.9 billion check for a drug still in trials shows how far they will go to buy the next franchise.
